TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03395405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: One 500 mg tablet twice daily with food for 56 consecutive doses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet twice daily with food for 56 consecutive doses
Study: NCT02580708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Study: NCT00778128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-4126
Description: Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-4126
Description: Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression
Study: NCT03944525

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula
Description: Oxygen-therapy via HFNC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: Non-invasive CPAP ventilation
Study: NCT03813238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-50717
Description: Dosage ranging from 6 mg to 48 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage ranging from 6 mg to 48 mg.
Study: NCT05190250

Intervention type: DIAGNOSTIC_TEST
Intervention: Pipelle biopsy
Description: Ultrasonographically confirmed implantation window. Collection of material with use of Pipelle biopsy. Collection of 5 ml venous blood.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pipelle biopsy
Description: Ultrasonographically confirmed implantation window. Collection of material with use of Pipelle biopsy. Collection of 5 ml venous blood.
Study: NCT02080871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stenting of the Common and/or External Iliac Arteries
Description: Balloon expandable stenting of iliac occlusive disease.
Study: NCT02507518

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET scan imaging
Description: a PET scan will be done 2 weeks before the start of maintenance therapy and another 16 days after to predict the earlier response to treatment
Study: NCT01941732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Study: NCT02745665

Intervention type: OTHER
Intervention: flow mediated dilation (endothelial function)

Intervention type: OTHER
Intervention: flow mediated dilation (endothelial function)

Intervention type: OTHER
Intervention: flow mediated dilation (endothelial function)

Intervention type: OTHER
Intervention: ABPI

Intervention type: OTHER
Intervention: ABPI

Intervention type: OTHER
Intervention: ABPI

Intervention type: OTHER
Intervention: Pulse wave velocity and augmentation index

Intervention type: OTHER
Intervention: Pulse wave velocity and augmentation index

Intervention type: OTHER
Intervention: Pulse wave velocity and augmentation index

Intervention type: OTHER
Intervention: blood pressure

Intervention type: OTHER
Intervention: blood pressure

Intervention type: OTHER
Intervention: blood pressure

Intervention type: OTHER
Intervention: ramp test

Intervention type: OTHER
Intervention: ramp test

Intervention type: OTHER
Intervention: ramp test
Study: NCT02710279

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Trier Social Stress Test (TSST)
Description: For the TSST the participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. Three successive phases: (1) A preparation period (3 min), (2) a free speech: explain why you are the best candidate for the job (5 min), (3) a mental arithmetic complex task (5 min). The two tasks (task 2 and 3) are performed in front of a selection committee, three persons dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback. Additionally, participants are told that they are video-taped and told that their performance will be evaluated. (in fact, there is no video-tape, just a false camera). After the TSST, patients have to answer to a questionnaire on their smartphone, 5 times a day during 7 days.

Intervention type: DEVICE
Group type: OTHER
Intervention: smartphone
Study: NCT01939873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KRISTELLER
Study: NCT01271348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: Etoricoxib film tablet, 90 mg, q.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet, q.d.
Study: NCT01174420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of ologen Collagen Matrix in trabeculectomy
Description: After trabeculectomy, place ologen Collagen Matrix on the top of the scleral flap under the conjunctiva before suturing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use of Mitomycin-C in trabeculectomy
Description: After creating a scleral flap, a sponge with Mitomycin-C (0.02%) is applied on the scleral surface for 3 minutes. Afterwards, Mitomycin-C was rinsed out with balanced salt solution.
Study: NCT03820856

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture plus fire needle therapy
Description: The protocol used in this group was the same as that used in the acupuncture alone group except that fire needle therapy was added. The treatments were administered twice weekly for 6 weeks. Fire needle therapy was performed as follows: an acupuncture needle made of tungsten was heated until red-hot over a lighter and then inserted into the two Ah shi points (the tender points on the common extensor tendon, specifically extensor carpi radialis). The red-hot needle was inserted rapidly into the Ah shi point (approximately 5-8 fen deep, 1 cun = 10 fen) for approximately half a second and then removed. Pressure was then applied to the needle hole using a sterilized dry cotton ball.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: We selected acupoints that have often been recommended for the treatment of lateral epicondylitis. Triple needling was performed at the Ah shi point, i.e., the 1-2-cm area encompassing the most painful spot on the humeral epicondyle. We also manipulated acupuncture needles in the following areas: LI10 (Shousanli), LI11 (Quchi), LI12 (Zhouliao) and LU5 (Chize). The treatments were administered twice weekly for 6 weeks.
Study: NCT02771444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomo Assessment
Description: A four-view tomosynthesis examination
Study: NCT03338894

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Yoga
Description: 1 Hour yoga class
Study: NCT04900129

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm%
Description: inhaled vapor containing Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm% twice daily in addition to conventional treatment. That is, 100 gram of emulsion contain diclofenac sodium 1 gram, N-acetyl cysteine 1.2 gm, menthol 20 mg, and methyl salicylic acid 50 mg.
Study: NCT02340741

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional prophylaxis of aeroembolism
Description: 167 patients will be enrolled. Will perform standard way of aeroembolism prevention

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional prophylaxis plus CO2 insufflation
Description: 167 patients will be enrolled. Will perform standard way of aeroembolism prevention and insufflation of carbon dioxide

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cardiac surgery with opening of heart chambers
Description: Patients with different clinical diagnoses, which is planned to cardiac surgery with the opening heart cavities

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cardiac surgery with opening of heart chambers
Description: Patients with different clinical diagnoses, which is planned to cardiac surgery with the opening heart cavities
Study: NCT02982525

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: No Mussels
Description: Habitual diet only

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: One mussel portion
Description: 1 x 75g mussel portions provided per week

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Two mussel portions
Description: 2 x 75g mussel portions provided per week

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Three mussel portions
Description: 3 x 75g mussel portions provided per week
Study: NCT03476629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Effects of different physical activity programs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Effects of different physical activity programs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Effects of different physical activity programs
Study: NCT03757455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS protocol postoperative actions
Description: Postoperatively:~Mobilization with nurses assisted Drinks allowed after 4h surgery~POP 1:~Drinking and normal food Removal of urinary catheter Intravenous liquids only if needed Mobilization Pain management by epidural cannula Discussion of the ERAS protocol Pancreatin capsules per os before eating~Postoperative day 2:~- Mobilization: As much as possible, autonomous movement~Postoperative day 3:~Ending epidural infusion cannula removal Mobilization as independently as possible~Pain relief: oxycodone/naloxone p.o. to keep mobilization possible:~Postoperative day 4:~Support and encouragement continues Pain management at a level that allows mobility
Study: NCT03622502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.5mcg/kg was infused over 10 min before end of the surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 2.0 ng/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 2.0 ng/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline was infused over 10 min before end of the surgery
Study: NCT03112356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-Leukoscan® scintigraphy
Description: Gated single photon emission computed tomography with co-registered computer tomography (gated SPECT-CT) 6 hours and 24 hours after infusion of 99mTc-Leukoscan (1000 MBq)
Study: NCT04690413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOWDx COVID-19 Test
Description: The investigational device is the NOWDx COVID-19 Test.
Study: NCT01729936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting time Change Intervention
Description: Intervention to find alternatives to substitute sitting time by doing the regular activities standing or walking.
Study: NCT02232074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient navigation enhanced with legal support
Study: NCT02607800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg tablet administered orally once daily with food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOF/VEL
Description: 400/100 mg tablet administered orally once daily with or without food
Study: NCT04372836

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vasopressin injection
Description: The intervention consists of five steps: rupture the ovarian endometrial cyst and remove the ''chocolate fluid;'' inject diluted vasopressin solution into the interface between endometrioma and ovarian parenchyma; stop injecting until the solution overflow; separate the endometrioma away from the ovarian parenchyma; and coagulate bleeding spots and suture the ovary.
Study: NCT02811146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart rehabilitation
Description: Heart rehabilitation, for 12 weeks, 3 times a week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart rehabilitation
Description: Heart rehabilitation, for 12 weeks, 3 times a week
Study: NCT02311205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Transarterial Chemoembolization (TACE)
Description: On demand conventional TACE will be performed in all the patients after enrollment and can be continued until intrahepatic CR, TACE failure or consent withdrawal. Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
Study: NCT02445313

Intervention type: DEVICE
Intervention: Nidek MP-3
Description: Nidek MP-3 device to be used to take images which will allow measurement of GA in patients with AMD

Intervention type: DEVICE
Intervention: Nidek MP-3
Description: Nidek MP-3 device to be used to take images which will allow measurement of GA in patients with AMD
Study: NCT02855307

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 60-minute exercise
Description: Patients will be admitted at the research clinical facility at 6:30. The artificial pancreas intervention will start at 7:00. A standardized breakfast will be served at 8:00. At 9:30, patients will performed a 60-minute exercise on the ergocycle at 60% of VO2 max. At 11:30, patients will be switched to standard insulin pump therapy and a lunch will be served. Patients will be discharged after lunch consumption.
Study: NCT02811146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart rehabilitation
Description: Heart rehabilitation, for 12 weeks, 3 times a week
Study: NCT02855307

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 60-minute exercise
Description: Patients will be admitted at the research clinical facility at 6:30. The artificial pancreas intervention will start at 7:00. A standardized breakfast will be served at 8:00. At 9:30, patients will performed a 60-minute exercise on the ergocycle at 60% of VO2 max. At 11:30, patients will be switched to standard insulin pump therapy and a lunch will be served. Patients will be discharged after lunch consumption.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 60-minute exercise
Description: Patients will be admitted at the research clinical facility at 6:30. The artificial pancreas intervention will start at 7:00. A standardized breakfast will be served at 8:00. At 9:30, patients will performed a 60-minute exercise on the ergocycle at 60% of VO2 max. At 11:30, patients will be switched to standard insulin pump therapy and a lunch will be served. Patients will be discharged after lunch consumption.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: Patient's insulin pump will be used to infuse insulin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: Patient's insulin pump will be used to infuse insulin.
Study: NCT02553239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolLoop®
Description: Cryoablation of Atrial Fibrillation Using the CoolLoop Cryoablation System
Study: NCT01107535

Intervention type: BIOLOGICAL
Intervention: Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice.
Description: Synagis (palivizumab) administered according to usual clinical practice. After the enrollment visit, subjects will have monthly visits until they have received the complete Synagis immunization regimen of their hospital, then they will have 2 follow up visits, one of them 30 days after the fifth dose of Synagis and the other visit at one year of age.
Study: NCT04576767

Intervention type: OTHER
Intervention: anaesthetic
Description: different states of consciousness

Intervention type: OTHER
Intervention: anaesthetic
Description: different states of consciousness
Study: NCT00135395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir+ritonavir
Description: Capsules, Oral, 300mg/100mg, once daily, 24 weeks.
Study: NCT02713360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Study: NCT03485807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Description: 2 week SmartPhone-based mindfulness training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Coping Training (CT)
Description: 2 week SmartPhone-based structurally equivalent coping training
Study: NCT02855307

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: Patient's insulin pump will be used to infuse insulin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 Platinum glucose sensor
Description: The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
Study: NCT00135395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir+ritonavir
Description: Capsules, Oral, 800mg/200mg, twice daily, 24 weeks.
Study: NCT02353000

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases

Intervention type: RADIATION
Group type: OTHER
Intervention: Whole Brain Radiotherapy
Description: Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases
Study: NCT04380220

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples and processing
Description: DSC perfusion technique at 3.0-T MRI only in MS patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples and processing
Description: DSC perfusion technique at 3.0-T MRI only in MS patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples and processing
Description: DSC perfusion technique at 3.0-T MRI only in MS patients
Study: NCT05403021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GETCare Intervention
Description: This 5-week intervention was administered remotely and individually to caregivers utilizing phone, email, and a secure online platform. The GETCare program was mostly self-led and included five weekly module education topics: basics of stroke, caregiver skills, caregiver changes, meaningful participation, and community resources. Each module incorporated (1) individualized education, (2) goal setting, (3) skills training, and (4) community resource recommendations. The program was led by a licensed occupational therapist who is a certified stroke rehabilitation specialist. The occupational therapist conducted weekly check-ins via email or phone focused on answering questions, tracking goal progress, and assisting in problem solving.
Study: NCT03356587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day
Study: NCT03246932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led psycho-education group
Description: A structured, researcher-designed peer-led psycho-education program (6 months), comprising of 12 bi-weekly, 2-hour group sessions.
Study: NCT03991650

Intervention type: BEHAVIORAL
Intervention: Monitoring with a device
Description: Participants will be monitored by an App.

Intervention type: BEHAVIORAL
Intervention: Monitoring with a device
Description: Participants will be monitored by an App.
Study: NCT03363776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986277
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986277
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986277
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT01564108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Series of intravitreal injections of Ranibizumab
Study: NCT03246932

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Profession-led psycho-education group
Description: A psychoeducation group program (12 sessions, bi-weekly).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine psychiatric care
Description: Routine psychiatric outpatient care, or Treatment-as-usual (TAU).
Study: NCT02855307

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 Platinum glucose sensor
Description: The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 Platinum glucose sensor
Description: The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
Study: NCT03246932

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine psychiatric care
Description: Routine psychiatric outpatient care, or Treatment-as-usual (TAU).

Intervention type: OTHER
Group type: OTHER
Intervention: Routine psychiatric care
Description: Routine psychiatric outpatient care, or Treatment-as-usual (TAU).
Study: NCT00870909

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: Intensity 2 mA during 20 minutes, 2 times per day

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham tDCS
Description: sham condition as delivered by the stimulator
Study: NCT01185288

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab in pre-filled syringes